KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arbutus Biopharma (ABUS) Total Current Liabilities: 2009-2025

Historic Total Current Liabilities for Arbutus Biopharma (ABUS) over the last 15 years, with Sep 2025 value amounting to $5.2 million.

  • Arbutus Biopharma's Total Current Liabilities fell 72.60% to $5.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.2 million, marking a year-over-year decrease of 72.60%. This contributed to the annual value of $15.6 million for FY2024, which is 30.55% down from last year.
  • As of Q3 2025, Arbutus Biopharma's Total Current Liabilities stood at $5.2 million, which was up 3.23% from $5.0 million recorded in Q2 2025.
  • Over the past 5 years, Arbutus Biopharma's Total Current Liabilities peaked at $32.9 million during Q4 2022, and registered a low of $5.0 million during Q2 2025.
  • Its 3-year average for Total Current Liabilities is $18.3 million, with a median of $20.3 million in 2024.
  • As far as peak fluctuations go, Arbutus Biopharma's Total Current Liabilities surged by 384.22% in 2022, and later tumbled by 77.77% in 2025.
  • Arbutus Biopharma's Total Current Liabilities (Quarterly) stood at $11.2 million in 2021, then spiked by 192.82% to $32.9 million in 2022, then plummeted by 31.56% to $22.5 million in 2023, then plummeted by 30.55% to $15.6 million in 2024, then crashed by 72.60% to $5.2 million in 2025.
  • Its last three reported values are $5.2 million in Q3 2025, $5.0 million for Q2 2025, and $19.4 million during Q1 2025.